Mary Ellen Moynahan

Mary Ellen Moynahan

UNVERIFIED PROFILE

Are you Mary Ellen Moynahan?   Register this Author

Register author
Mary Ellen Moynahan

Mary Ellen Moynahan

Publications by authors named "Mary Ellen Moynahan"

Are you Mary Ellen Moynahan?   Register this Author

30Publications

923Reads

33Profile Views

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.

J Clin Oncol 2018 04 22;36(10):981-990. Epub 2018 Feb 22.

Dimitrios Zardavas and Debora Fumagalli, Breast International Group; Christos Sotiriou, Université Libre de Bruxelles, Brussels, Belgium; Luc te Marvelde and Roger L. Milne, Cancer Council; Roger L. Milne and Sherene Loi, University of Melbourne, Melbourne; Barry Iacopetta, University of Western Australia, Western Australia; Sandra O'Toole and Elena Lopez-Knowles, Garvan Institute of Medical Research, Darlinghurst, Australia; George Fountzilas and Vassiliki Kotoula, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki; Evangelia Razis, Hygeia Hospital; George Papaxoinis, Hippokration Hospital, Athens, Greece; Heikki Joensuu, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Mary Ellen Moynahan, Memorial Sloan Kettering Cancer Center, New York, NY; Bryan T. Hennessy, Beaumont Hospital and Royal College of Surgeons, Dublin, Ireland; Ivan Bieche, Curie Institut, Paris; Thomas Bachelot, Centre de Recherche en Cancérologie de Lyon, Lyon; Stefan Michiels, Gustave Roussy and Inserm, Univ. Paris-Sud, Univ. Paris-Saclay, Villejuif, France; Lao H. Saal, Lund University, Lund; Olle Stal, Qing Wang, and Gizeh Perez-Tenorio, Linköping University, Linköping, Sweden; Jeanette Dupont Jensen, University of Southern Denmark, on behalf of the Danish Breast Cancer Cooperative Group, Odense, Denmark; Elena Lopez-Knowles, Royal Marsden NHS Trust and Institute of Cancer Research, London; Daniel W. Rea, University of Birmingham, Birmingham, United Kingdom; Mattia Barbaraeschi, Santa Chiara Hospital, Trento, Italy; Shinzaburo Noguchi, Osaka University, Osaka Japan; Hatem A. Azim Jr, American University of Beirut (AUB), Beirut, Lebanon; Enrique Lerma, Universitat Autònoma de Barcelona, Barcelona, Spain; Cornelis J.H. can de Velde, Leiden University Medical Center, Leiden, the Netherlands; Vicky Sabine, University of Guelph, Guelph; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.8301DOI Listing
April 2018

PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells.

PLoS One 2016 18;11(7):e0159341. Epub 2016 Jul 18.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0159341PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948780PMC
July 2017

ATM loss leads to synthetic lethality in BRCA1 BRCT mutant mice associated with exacerbated defects in homology-directed repair.

Proc Natl Acad Sci U S A 2017 07 28;114(29):7665-7670. Epub 2017 Jun 28.

Developmental Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1706392114DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530697PMC
July 2017

Robust homology-directed repair within mouse mammary tissue is not specifically affected by Brca2 mutation.

Nat Commun 2016 10 25;7:13241. Epub 2016 Oct 25.

Developmental Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms13241DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093336PMC
October 2016

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).

J Clin Oncol 2016 08 2;34(22):2602-9. Epub 2016 May 2.

Maura N. Dickler, Mary Ellen Moynahan, Diana E. Lake, and Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; William T. Barry, Dana-Farber Cancer Institute; Eric P. Winer, Dana-Farber/Partners Cancer Care, Boston, MA; Constance T. Cirrincione, Duke University, Durham, NC; Matthew J. Ellis, Baylor College of Medicine; Debasish Tripathy, The University of Texas MD Anderson Cancer Center, Houston, TX; Federico Innocenti and Lisa A. Carey, University of North Carolina at Chapel Hill, Chapel Hill, NC; Arti Hurria, City of Hope, Duarte; Hope S. Rugo, University of California at San Francisco, San Francisco, CA; Olwen Hahn, Alliance for Clinical Trials in Oncology, Chicago, IL; and Bryan P. Schneider, Indiana University School of Medicine, Indianapolis, IN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.1595DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012690PMC
August 2016

When Genome Maintenance Goes Badly Awry.

Mol Cell 2016 06;62(5):777-87

Developmental Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molcel.2016.05.021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966655PMC
June 2016

Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.

Clin Cancer Res 2013 Oct 21;19(19):5505-12. Epub 2013 Aug 21.

Authors' Affiliations: Breast Cancer Medicine Service, Departments of Pathology, Biostatistics, and Radiology, Memorial Sloan-Kettering Cancer Center; Weill Medical College of Cornell University, New York; Dana-Farber Cancer Institute; Massachusetts General Hospital, Boston, Massachusetts; Mayo Clinic, Rochester, Minnesota; Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia; University of North Carolina at Chapel Hill, Chapel Hill; Duke University Medical Center, Durham, North Carolina; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California; University of Alabama at Birmingham, Birmingham, Alabama; and The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-3327DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086643PMC
October 2013

PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.

Breast Cancer Res Treat 2011 Sep 27;129(2):635-43. Epub 2011 May 27.

Department of Medicine and the Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-011-1601-4DOI Listing
September 2011

Homology-directed Fanconi anemia pathway cross-link repair is dependent on DNA replication.

Nat Struct Mol Biol 2011 Apr 20;18(4):500-3. Epub 2011 Mar 20.

Developmental Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nsmb.2029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273992PMC
April 2011

BRCA gene structure and function in tumor suppression: a repair-centric perspective.

Cancer J 2010 Jan-Feb;16(1):39-47

Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York City, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e3181cf0204DOI Listing
May 2010

Loss of 53BP1 is a gain for BRCA1 mutant cells.

Cancer Cell 2010 May;17(5):423-5

Developmental Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2010.04.021DOI Listing
May 2010

Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis.

Nat Rev Mol Cell Biol 2010 Mar;11(3):196-207

Developmental Biology Program, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrm2851DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3261768PMC
March 2010

PIK3CA mutation associates with improved outcome in breast cancer.

Clin Cancer Res 2009 Aug 11;15(16):5049-59. Epub 2009 Aug 11.

Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-0632DOI Listing
August 2009

BARD1 participates with BRCA1 in homology-directed repair of chromosome breaks.

Mol Cell Biol 2003 Nov;23(21):7926-36

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC207645PMC
http://dx.doi.org/10.1128/mcb.23.21.7926-7936.2003DOI Listing
November 2003

The cancer connection: BRCA1 and BRCA2 tumor suppression in mice and humans.

Oncogene 2002 Dec;21(58):8994-9007

Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1206177DOI Listing
December 2002

ATP hydrolysis by mammalian RAD51 has a key role during homology-directed DNA repair.

J Biol Chem 2002 Jun 28;277(23):20185-94. Epub 2002 Mar 28.

Cell Biology Program, Memorial Sloan-Kettering Cancer Center and Cornell University Graduate School of Medical Sciences, New York, New York 10021.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M112132200DOI Listing
June 2002